drugset / Trial / NCT00643500

Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy

NCT00643500

Phase 4 Completed 342 enrolled UCB Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with partial-onset seizures seen in community-based practices were to be included in this therapeutic use study * to assess the safety and tolerability of Keppra (Levetiracetam) and to confirm the favorable safety of the drug found during clinical development * to obtain further information about optimal dosing in daily clinical practice. Compared to previous registration trials, the study population corresponded more closely to that seen in daily clinical practice.

Timeline

Start
2002-01
Primary completion
2003-05
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified

Indications